Both stocks run through our valuation models. Here is how AbbVie (ABBV) and Merck & Company (MRK) compare, as of Aug 13, 2026.
As of Aug 13, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: AbbVie trades at $249 versus a fair value of $67.72 (-73%), while Merck & Company trades at $133 versus $125 (-6%).
AbbVie
ABBV · USD · Health Care
-73%
upside to fair value
overvalued
Price$249
Fair Value$67.72
Quality74/100
Merck & Company
MRK · USD · Health Care
-6%
upside to fair value
fairly valued
Price$133
Fair Value$125
Quality70/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
AbbVieMerck & Company
Valuation
118.9×P/E (TTM)38.5×
7.16×P/S (TTM)4.64×
—P/B5.80×
16.8×EV/EBITDA11.4×
0.40×PEG6.10×
2.8%Dividend yield2.6%
$6.74Dividend per share$3.28
Profitability
6%Net margin14%
32%Operating margin39%
62%Return on equity19%
10%Return on assets13%
Growth
12%Revenue growth (YoY)5%
1.8%Avg. growth/yr (3Y)3.1%
6.0%Avg. growth/yr (5Y)9.4%
Balance & size
—Debt / equity0.89×
$449BMarket cap$305B
healthyGrowth qualityhealthy
Merck & Company leads: 4 to 8 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
AbbVieof which business quality 68 · market factors 75Merck & Companyof which business quality 68 · market factors 85
ProfitabilityMargins and returns on capital today
39
74
Quality GrowthAre margins and returns improving?
58
36
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
100
71
Low VolatilityCalm price path (market factor)
88
86
MomentumPrice trend over the last 3–12 months (market factor)
66
75
52W MomentumDistance to the 52-week high (market factor)
75
100
Net IssuanceBuybacks instead of dilution
82
91
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
AbbVie
DCF Models$117
Earnings-Based$42.53
Dividend Discount$126
Multiples$73.45
Growth DCF$151
Economic Profit$111
Growth Earnings$40.81
23 of 23 models see the stock below the current price.
Merck & Company
DCF Models$117
Earnings-Based$62.77
Dividend Discount$60.35
Multiples$122
Asset-Based$14.27
Growth DCF$74.00
Economic Profit$83.85
Growth Earnings$138
19 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
AbbVie
Bear $39.47Fair Value $67.72Bull $98.87
$249 = current price (white tick)
Merck & Company
Bear $70.92Fair Value $125Bull $188
$133 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
AbbVie · Health Care
Quality score74 · Top 25%
Fair value upside-73% · bottom 25%
Merck & Company · Health Care
Quality score70 · Top 25%
Fair value upside-6% · above median
Bottom line
As of Aug 13, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: AbbVie trades at $249 versus a fair value of $67.72 (-73%), while Merck & Company trades at $133 versus $125 (-6%).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
